ObsEva SA.

NASDAQ:OBSV  
2.02
-0.09 (-4.26%)
Products

Obseva Announces U.S. FDA Acceptance Of New Drug Application For Linzagolix

Published: 11/22/2021 06:27 GMT
ObsEva SA. (OBSV) - Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix.
FDA Set a Target Action Date of September 13, 2022 for This NDA Under Prescription Drug User Fee Act (pdufa).
Linzagolix Marketing Authorization Application Was Validated by Ema for Human Use (chmp) Expected in Q4 2021.